A new method to measure plasma levels of activated protein C in complex with protein C inhibitor in patients with acute coronary syndromes
The role of platelet factor 4 in platelet aggregation induced by the antibodies implicated in heparin-induced thrombocytopenia
Thrombolytic effect of lonomin V in a rabbit jugular vein thrombosis model
Comparative study of platelet activation markers in diabetes mellitus patients complicated by cerebrovascular disease
Tissue factor and thrombomodulin levels are correlated with stage of cirrhosis in patients with liver disease
Idiopathic osteonecrosis in an adult with familial protein S deficiency and hyperhomocysteinemia
The use of recombinant factor VIIa (NovoSeven®) in a patient with a factor XI deficiency and a circulating anticoagulant
Thromboelastography: a reliable test?
Improved confirmation of weak lupus anticoagulants by employing sensitive and insensitive reagents to the lupus anticoagulant
Modification of the ProC® Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation
Comparison of three methods for measuring PEG-hirudin in blood
Disagreement between bedside and laboratory activated partial thromboplastin time and international normalized ratio for various novel anticoagulants
Prevalence of antithrombin deficiency in patients with chronic leg ulcer
Therapy of isolated calf muscle vein thrombosis with low-molecular-weight heparin
O-1 The effect of methylene blue treatment on fibrinogen
O-2 Tissue plasminogen activator antigen and coronary heart disease: new prospective study and meta-analyses.
O-3 Induction of both tissue factor expression in monocytes by lipoprotein-complexed C reactive protein: a possible mechanism underlying the adverse outcome predicted by waveform analysis
O-4 False negative compression ultrasound in patients with suspected DVT and elevated D-dimers
O-5 Correction of abnormal thrombin generation in FVIII deficient plasma by low concentrations of FVIII
O-6 Inhibitory vWF-cleaving protease activity may predict clinical response in acute thrombotic thrombocytopenic purpura
O-7 Eleven year single centre experience of liver transplantation for end stage liver disease in haemophilic patients
O-8 Immune tolerance therapy for factor VIII auto-antibodies. A single centre experience
O-9 The relationship between plasma concentration of alpha 2 macroglobulin and ABO blood group
O-10 A chromogenic substrate assay for high molecular weight kininogen: evaluation and use for the measurement of high molecular weight kininogen levels in cardiopulmonary patients
O-11 A type 2 von willebrand disease family with an unusual phenotype and ARG 1315 CYS mutation: type 2A or type 2M?
O-12 Recombinant factor VIIa activates platelets in whole blood
O-13 Clinical signficance of beta2-glycoprotein I polymorphisms VAL247LEU and TRP316SER in an antiphospholipid syndrome (aps) population
O-14 A study of monocyte tissue factor expression, platelet-leucocyte conjugates, platelet and endothelial activation in patients with non-rheumatic persistent atrial fibrillation
O-15 Aspirin inhibition of arachidonic acid mediated platelet aggregation is significantly reduced during surgery
O-16 Influence of flow on inhibition of platelet dependent thrombin generation by anti-GPIIb/IIIa and GPIbα antibodies
O-17 Lysis of fibrin by polymorphonuclear cells from septic patients
O-18 Oxidized low density lipoprotein increases procoagulant status of atherosclerotic lesion via intrinsic pathway of blood coagulation
O-19 Molecular modelling of mutations in human factor X
O-20 In vitro and in vivo consequences of the sepsis effect on the endothelial cell protein C receptor
P-1 A novel mutation in factor X: isoleucine 411 phenylalanine resulting in a bleeding tendency associated with low factor X protein and activity levels
P-2 Intracranial haemorrhage in a tertiary paediatric centre: a survey of 100 children with severe haemophilia
P-3 A new candidate type 2M Von Willebrand disease mutation in an asymptomatic patient with absent ristocetin but normal botrocetin activity and a daughter with type 3 VWD
P-4 Evaluation of the PFA-100 R as a potential screening tool for platelet dysfunction
P-5 An evaluation of genetic analysis in the diagnosis of type 2A, 2B and 2M von Willebrand disease
P-6 Optimising approaches and techniques for the provision of a comprehensive carrier and antenatal diagnostic service for haemophilias A and B
P-7 Use of recombinant factor VIIa in platelet disorders – a single centre experience
P-8 Anticardiolipin antibodies and pregnancy outcome: a prospective study in an unselected obstetric population
P-9 Characterisation of a commercial EIA for plasma homocysteine
P-10 Haemostatic and inflammatory variables and prevalent cardiovascular disease: British regional heart study
P-11 Audit of usefulness of β2GP1 in the assessment of the antiphospholipid syndrome.
P-12 The GLN27GLU beta-2 adrenoreceptor polymorphism is associated with elevation of FVIII:C and venous thromboembolism
P-13 Detection of factor V Leiden and prothrombin G22210A in whole blood using the lightcycler system TM
P-14 Tissue factor independent PCA of T lymphoblastoid cell lines: relationship to stage of differentiation.
P-15 Thromboelastography in general haemostasis in Southampton University Hospitals
P-16 Sigma AMAX 190 coagulometer: evaluation and performance characteristics for use in a routine clinical laboratory.
P-17 Evaluation of Sysmex CA50 for routine use
P-18 Successful treatment of congenital thrombotic thrombocytopenic purpura using the intermediate purity plasma derived factor VIII concentrate BPL 8Y
P-19 A systematic review of outcome measures used to define oral anticoagulation therapeutic control
P-20 Demonstration of the sensitivity of thromboelastography for detecting the presence of heparins and heparinoids
P-21 The therapeutic potential of Desmopressin in Ehlers Danlos Syndrome: a case report
P-22 Response to anti-viral therapy for chronic hepatitis C infection in patients with haemophilia and von Willebrand's disease: correlation with serum hyaluronic acid levels
P-23 Inhibitor formation in a patient with inherited factor XI deficiency
P-24 An unusual type 2A von Willebrand disease phenotype with associated thrombocytopaenia
P-25 Inverse relationship between plasma von Willebrand factor and soluble P-selectin in patients with type 1 but not type 2 von Willebrand disease
P-26 Ristocetin cofactor activity remains an essential test in von Willebrand disease screen for type 1 individuals
P-27 Detection of D-dimers in cerebral spinal fluid (CSF-DD) using a routine D-dimer assay: exclusion of sub-arachnoid haemorrage and meningitis
P-28 Early identification of the risk of mortality, the development of disseminated intravascular coagulation (DIC) and the diagnosis of sepsis through waveform analysis in a simple assay of coagulation
P-29 Alternatives for the provision of a regional anticoagulation service: Goodbye Yellow Book Road!
P-30 The local formulation of a protocol for the administration of intravenous heparin to improve medical compliance and patient therapeutic control
P-31 A child with a positive lupus anticoagulant who underwent repair of a ventricular septal defect
P-32 Reference ranges for fibrin D-dimer and other haemostatic/inflammatory variables in men aged 60–79 years: implications for diagnosis of venous thromboembolism, inflammation and bleeding disorders
P-33 Physical activity and haemostatic and inflammatory variables in older men
P-34 Acquired activated protein C resistance in antiphospholipid patients is independent of IgG β 2 -glycoprotein-I antibodies
P-35 The pharmacokinetics of Ximelagatran following single and repeated oral dosing to healthy male subjects
P-36 Inter-laboratory variation in antiphospholipid antibody testing
P-37 Does factor XII have a role in fetal development?
P-38 D-dimers of > 1,000 in patients with proven DVT are suggestive of cancer
P-39 Interleukin-6 as a predictor of coronary heart disease
P-40 Are supranormal factor VII levels a risk factor for pregnancy related venous thromboembolic disease